PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
-10.22%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$3.18B
AUM Growth
+$3.18B
(-36%)
Cap. Flow
-$557M
Cap. Flow
% of AUM
-17.5%
Top 10 Holdings %
Top 10 Hldgs %
52.9%
Holding
144
New
7
Increased
15
Reduced
49
Closed
31
Top Buys
| 1 |
Amylyx Pharmaceuticals
AMLX
|
$39.8M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$39.6M |
| 3 |
Lyra Therapeutics
LYRA
|
$33.5M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$32.6M |
| 5 |
Eli Lilly
LLY
|
$32.4M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$143M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$52.5M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
$34.5M |
| 4 |
Penumbra
PEN
|
$31.9M |
| 5 |
Travere Therapeutics
TVTX
|
$30.9M |
Sector Composition
| 1 | Healthcare | 84.05% |
| 2 | Consumer Discretionary | 0.04% |
| 3 | Financials | 0% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $26.4M | 0.83% |
3,645,471
-1,050,377
| -22% | -$7.6M |
|
27
Madrigal Pharmaceuticals
MDGL
$9.7B
| $26.3M | 0.82% |
367,501
+89,215
| +32% | +$6.39M |
|
28
Alnylam Pharmaceuticals
ALNY
$58.6B
| $25.2M | 0.79% |
172,991
-7,088
| -4% | -$1.03M |
|
29
Nautilus Biotechnolgy
NAUT
$80.7M
| $24.5M | 0.77% |
9,111,151
| – | – |
|
30
Procept Biorobotics
PRCT
$2.11B
| $24.5M | 0.77% |
749,700
-738,584
| -50% | -$24.1M |
|
31
ADMA Biologics
ADMA
$4.03B
| $22.8M | 0.71% |
11,521,102
-412,285
| -3% | -$816K |
|
32
Nuvalent
NUVL
$5.74B
| $22.4M | 0.7% |
1,655,007
-96,594
| -6% | -$1.31M |
|
33
Establishment Labs
ESTA
$1.11B
| $22.1M | 0.69% |
405,759
-44,615
| -10% | -$2.43M |
|
34
Zymeworks
ZYME
$1.07B
| $21.9M | 0.69% |
4,132,534
-1,193,081
| -22% | -$6.32M |
|
35
Immatics
IMTX
$662M
| $21.8M | 0.68% |
2,500,000
| – | – |
|
|
INBX
36
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $21.7M | 0.68% |
1,914,592
+133,357
| +7% | +$1.51M |
|
37
Arcellx
ACLX
$3.95B
| $20.6M | 0.65% |
+1,141,990
| New | +$20.6M |
|
|
ISEE
38
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $20.1M | 0.63% |
2,087,956
-3,137,459
| -60% | -$30.2M |
|
39
Harmony Biosciences
HRMY
$2.16B
| $20.1M | 0.63% |
+411,804
| New | +$20.1M |
|
40
Tarsus Pharmaceuticals
TARS
$2.44B
| $18.9M | 0.59% |
1,296,416
| – | – |
|
41
Artivion
AORT
$2.04B
| $17.6M | 0.55% |
929,705
+314,002
| +51% | +$5.93M |
|
|
DICE
42
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $16.3M | 0.51% |
1,051,904
-463,457
| -31% | -$7.19M |
|
43
Rocket Pharmaceuticals
RCKT
$358M
| $16.1M | 0.5% |
1,166,883
-511,207
| -30% | -$7.03M |
|
44
BridgeBio Pharma
BBIO
$9.91B
| $15.4M | 0.48% |
1,697,033
-2,142,347
| -56% | -$19.5M |
|
45
BioMarin Pharmaceuticals
BMRN
$11.3B
| $14.9M | 0.47% |
+180,000
| New | +$14.9M |
|
46
Outset Medical
OM
$245M
| $14.8M | 0.46% |
998,727
-884,672
| -47% | -$13.1M |
|
47
Athira Pharma
ATHA
$15.5M
| $14.6M | 0.46% |
4,797,278
+1,371,362
| +40% | +$4.18M |
|
|
48
Apellis Pharmaceuticals
APLS
$3.51B
| $14.5M | 0.46% |
321,300
-1,160,400
| -78% | -$52.5M |
|
|
49
Travere Therapeutics
TVTX
$1.75B
| $13.8M | 0.43% |
570,084
-1,275,471
| -69% | -$30.9M |
|
|
RAIN
50
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $13.8M | 0.43% |
2,483,619
| – | – |
|